On February 3, 2023, Matthew Roden, a member of the Board of Directors (the Board) of iTeos Therapeutics, Inc. (the Company), notified the Company of his decision to resign from the Board, effective immediately. Dr. Roden's resignation is not as a result of any disagreement between him and the Company, its management, the Board or any committee of the Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.09 USD | +0.22% | +6.29% | +65.21% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.21% | 673M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- ITOS Stock
- News iTeos Therapeutics, Inc.
- ITeos Therapeutics, Inc. Announces Resignation of Matthew Roden from the Board